A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy

Malignant pleural mesothelioma (MPM) is a neoplasm with inferior prognosis and notorious chemotherapeutic resistance. Targeting aberrantly overexpressed kinases to cure MPM is a promising therapeutic strategy. Here, we examined ALK, MET and mTOR as potential therapeutic targets and determined the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Mönch, Dina, Bode-Erdmann, Sabine, Kalla, Jörg, Sträter, Jörn, Schwänen, Carsten, Falkenstern-Ge, Roger, Klumpp, Siegfried, Friedel, Godehard, Ott, German, Kalla, Claudia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945506/
https://www.ncbi.nlm.nih.gov/pubmed/29755689
http://dx.doi.org/10.18632/oncotarget.25111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945506/
https://www.ncbi.nlm.nih.gov/pubmed/29755689
http://dx.doi.org/10.18632/oncotarget.25111

Ejemplares similares